Korea Institute of Radiological & Medical Sciences

Jie Young Song

Hee Chung Kwon

Sang Jun Park

Yang Hyun Kim

Eun Ju Lee

Ah Young Kim

Eun Sook Kim

Hyun Jin Shin

Kee Ho Lee

In Sung Jung

Ji Yeon Ahn

Sang Gu Hwang

Ky Youb Nam

Chun Ho Kim

Jae Sung Kim

Seung Yong Seo

Eun Ran Park

Yuan Yue

Kyung Hee Koo

Sung Sub Kim

Yi Na Yoon

Mi-yeun Kim

Saelooom Lee

Hyun Kyung Choi

Arang Son

Hong Duck Um

Mi Hyoung Kim

Min Jin Lim

Sae Lo Oom Lee

Yeon Sook Yun

Sarah Park

The present invention relates to a pharmaceutical composition for preventing or treating cancer, a radiosensitizer composition for treating cancer, and a health functional food for preventing or improving cancer, which comprise N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition comprising N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide or a derivative thereof as an active ingredient according to the present invention arrests the mitosis of cancer cells to prevent proliferation and at the same time, to exhibit low toxicity in normal cell lines and induce apoptosis only in cancer cell lines, so it can be used as an effective anticancer agent. In addition, the N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide of the present invention can increase the sensitivity of the treated cancer cells to radiation, so it can be used as a radiosensitizer composition for cancer treatment.

Pharmaceutical composition for preventing or treating cancer, containing N-1H-benzimidazol-2-yl-3-(1H-pyrrole-1-yl)benzamide as active ingredient

Melanophilin (MLPH) of the present invention is involved in differentiation into an adipocyte or fat accumulation, and accordingly, obesity can be treated or prevented by inhibiting the MLPH. Further, by measuring an expression level of the MLPH, obesity can be diagnosed and treated, and therapeutic agents for obesity and agents regulating differentiation into adipocytes can be screened.

Pharmaceutical composition for treating or preventing obesity

A substance inhibiting the expression of CCND3 gene or PAK2 gene, the substance containing a nucleotide such as miR-4779, may be efficiently used for preventing or treating cancer. In addition, by screening the substance that inhibits the expression of CCND3 gene or PAK2 gene, a candidate substance for preventing or treating cancer may be selected.

Cancer-treating pharmaceutical composition inhibiting expression of CCND3 or PAK2 gene

Disclosed is an anticancer supplement agent including a benzo[d]oxazole derivative as an effective ingredient. The benzo[d]oxazole derivative, which is a nuclear factor E2-related factor 2 (Nrf2) inhibitor, is capable of inhibiting activity of Nrf2 that induces an antioxidant enzyme to remove reactive oxygen species (ROS) that kills a cancer cell, thereby increasing production of ROS. Therefore, the benzo[d]oxazole derivative can be used as an anticancer supplement agent that shows therapeutic effects in anticancer agent therapy or radiation therapy, and in this regard, the benzo[d]oxazole derivative can overcome tolerance of the cancer cell to anticancer agent therapy or radiation therapy and enhance apoptotic effects on the cancer cell.

Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient

Provided are a method of enhancing radiation sensitivity by using miR-499b-5p and a method of treating a radiation resistant cancer including administering miR-499b-5p.

Composition comprising miRNA for enhancing radiation sensitivity

Growing community of inventors

Seoul, South Korea

Jie Young Song